Sirolimus Solution
Product Images NDC 31722-316

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Sirolimus (NDC 31722-316). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Camber-logo-2 (Camber Logo 2)

FDA Label Image

Camber-logo-3 (Camber Logo 3)

FDA Label Image
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
This appears to be a table showing the number of subjects in a study for two different phases: Treatment Phase and Observation Phase. The study involves the use of Sirolimus and Placebo, with different numbers of subjects in each group for both phases.*
FDA Label Image

Sirolimuscontainer (Sirolimuscontainer)

Sirolimuscontainer (Sirolimuscontainer)
Description: This is information regarding Sirolimus Oral Solution, intended for oral use only. Each 1 mL of the solution contains 1 mg of sirolimus, along with 1.5% to 2.5% ethanol. Other components include propylene glycol, phosphatidylcholine derived from soy lecithin, and polysorbate 80. The medication guide should be provided to each patient by the pharmacist. The recommended storage is refrigerated at 2° to 8°C, protected from light, and the contents should be used within 1 month after opening. For dosage instructions and more details, refer to the accompanying prescribing information. Keep the solution out of reach of children.*
FDA Label Image

Sirolimusinnercarton (Sirolimusinnercarton)

Sirolimusinnercarton (Sirolimusinnercarton)
This is a description of Sirolimus Oral Solution, which is intended for oral use. Each mL of the solution contains 1 mg of sirolimus. It also contains 1.5% to 2.5% ethanol, propylene glycol, phosphatidylcholine derived from soy lecithin, and polysorbate 80. The solution is to be kept refrigerated at 2° to 8°C and protected from light. Once opened, the contents of the bottle should be used within 1 month. Pharmacies are advised to dispense the Medication Guide to each patient. The solution is manufactured by Camber Pharmaceuticals and Amnora Pharma Pvt. Ltd.*
FDA Label Image

Sirolimusoutercarton (Sirolimusoutercarton)

Sirolimusoutercarton (Sirolimusoutercarton)
This is a description of Sirolimus Oral Solution, a medication indicated for oral use only. Each milliliter contains 1 mg of sirolimus along with a mixture of propylene glycol, phosphatidylcholine, and polysorbate 80. The solution comes in a 60 mL patient kit which includes a glass bottle of solution, oral syringe adapters, amber oral syringes, and a carrying case. The usual dosage instructions and storage guidelines are provided. It is important to keep the medication refrigerated at 2° to 8°C and protected from light. The text also includes detailed instructions on how to use the solution, prepare the doses using the syringes, and store the medication properly. For further information or in case of questions, a contact number is provided along with a mention of the manufacturer.*
FDA Label Image

Sirolimuspicture1 (Sirolimuspicture1)

FDA Label Image

Sirolimuspicture2 (Sirolimuspicture2)

FDA Label Image

Sirolimuspicture3 (Sirolimuspicture3)

FDA Label Image

Sirolimuspicture4 (Sirolimuspicture4)

FDA Label Image

Sirolimuspicture5 (Sirolimuspicture5)

FDA Label Image

Sirolimuspicture6 (Sirolimuspicture6)

FDA Label Image

Sirolimuspicture7 (Sirolimuspicture7)

FDA Label Image

Sirolimuspicture8 (Sirolimuspicture8)

FDA Label Image

Sirolimusstructure (Sirolimusstructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.